MELINDA GONZALEZ: Open Payments
NPI 1760651186 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,387 in 139 payments from 15 companies in 2025. Trend: 2023 $959 · 2024 $2,386 · 2025 $2,387
Food & beverage: $2,387
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 42 | $611 |
| Madrigal Pharmaceuticals | 8 | $279 |
| Ipsen Biopharmaceuticals, Inc | 16 | $211 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $167 |
| Lilly USA, LLC | 10 | $165 |
| PFIZER INC. | 12 | $155 |
| GENZYME CORPORATION | 5 | $145 |
| Janssen Biotech, Inc. | 6 | $117 |
| Phathom Pharmaceuticals, Inc. | 8 | $105 |
Products named: REZDIFFRA, IQIRVO, LINZESS, XIFAXAN, OMVOH, RINVOQ, ENTYVIO, DUPIXENT.
Industry payments across TX — which companies pay providers there.
